William Blair analyst Matthew Phipps initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform rating.
3 Economists React To February Jobs Report: 50-Basis-Point Interest Rate Hike ‘Still On The Table’ For Fed
U.S. payrolls soared by 311,000 in February, maintaining a strong pace despite recent interest rate hikes aimed at dampening demand.